TABLE 2.
STAGE | LBA | SBA | Duodenal | Jejunal/Ileal | |||
---|---|---|---|---|---|---|---|
All Patients | CSS | CSS | Difference* | CSS | Difference* | CSS | Difference* |
I | 93.2% | 65.3% | 27.9% | 59.8% | 33.4% | 80.4% | 12.8% |
II | 83.8% | 55.0% | 28.8% | 47.6% | 36.2% | 62.8% | 21.0% |
III | 62.7% | 40.0% | 22.7% | 38.6% | 24.1% | 42.2% | 20.5% |
Patients with ≥8 LN | |||||||
I | 93.3% | 80.3% | 13.0% | 79.3% | 14.0% | 81.6% | 11.7% |
II | 85.8% | 69.9% | 15.9% | 70.9% | 14.9% | 69.5% | 16.3% |
III | 63.6% | 45.1% | 18.5% | 44.0% | 19.6% | 47.1% | 16.5% |
In comparison to LBA; Cancer specific survival adjusted by age, sex, race, tumor grade;
Abbreviations: SBA, small bowel adenocarcinoma; LBA, large bowel adenocarcinoma; LN, lymph node.